A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

NCT00993018 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

77

Enrollment

INDUSTRY

Sponsor class

Stopped Logistic reasons associated with the FDA-imposed clinical hold.

Conditions

Diabetic Neuropathy

Interventions

DRUG: JNJ-42160443 (1 mg)
DRUG: JNJ-42160443 (3 mg)
DRUG: JNJ-42160443 (10 mg)
DRUG: Placebo

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.